Bestat Group Appoints New Chairman of Trifecta
On April 23, 2026, Samuel Su, CEO of Bestat Group, visited Trifecta MedTek Co., Ltd. to formally announce the appointment of Dr. Leo Huang as the company's new Chairman, marking an important step in advancing post-acquisition integration and organizational development.
Trifecta MedTek officially joined Bestat Group in February 2026, becoming a key component in expanding the Group's one-stop service platform spanning from preclinical research to clinical trials. This leadership appointment reflects Bestat’s continued commitment to strengthening organizational alignment and supporting Trifecta's long-term growth.
Dr. Leo Huang has dedicated over a decade of service to Trifecta, making significant contributions to its operations and development. His extensive industry experience and deep understanding of the organization position him well to lead Trifecta into its next phase, while enhancing synergy within the Bestat Group.
Samuel Su noted that Bestat Group will continue to prioritize talent development and resource integration, reinforcing organizational governance and operational efficiency to further enhance service quality and competitiveness in the biopharmaceutical industry.
This appointment also aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 8: Decent Work and Economic Growth, by fostering sustainable talent development and a strong organizational environment, and SDG 9: Industry, Innovation and Infrastructure, by supporting continued innovation and advancement within the biotechnology sector.
Looking ahead, Bestat Group will continue to leverage its expertise, talent, and integrated resources to drive sustainable growth and achieve new milestones in the global biopharmaceutical landscape.
On April 23, 2026, Samuel Su, CEO of Bestat Group, visited Trifecta MedTek Co., Ltd. to formally announce the appointment of Dr. Leo Huang as the company's new Chairman, marking an important step in advancing post-acquisition integration and organizational development.
Trifecta MedTek officially joined Bestat Group in February 2026, becoming a key component in expanding the Group's one-stop service platform spanning from preclinical research to clinical trials. This leadership appointment reflects Bestat’s continued commitment to strengthening organizational alignment and supporting Trifecta's long-term growth.
Dr. Leo Huang has dedicated over a decade of service to Trifecta, making significant contributions to its operations and development. His extensive industry experience and deep understanding of the organization position him well to lead Trifecta into its next phase, while enhancing synergy within the Bestat Group.
Samuel Su noted that Bestat Group will continue to prioritize talent development and resource integration, reinforcing organizational governance and operational efficiency to further enhance service quality and competitiveness in the biopharmaceutical industry.
This appointment also aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 8: Decent Work and Economic Growth, by fostering sustainable talent development and a strong organizational environment, and SDG 9: Industry, Innovation and Infrastructure, by supporting continued innovation and advancement within the biotechnology sector.
Looking ahead, Bestat Group will continue to leverage its expertise, talent, and integrated resources to drive sustainable growth and achieve new milestones in the global biopharmaceutical landscape.